Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19009075 | 0.78 | NR4A2 (0.59) | SMN1; SMN2MEN1KMT2AHTTGALR3 | |
| SCHEMBL28644110 | 0.77 | ALDH1A1 (0.56) | SMN1; SMN2MEN1KMT2AHTTGALR3 | |
| SCHEMBL9588763 | 0.75 | CYP2C19 (0.63) | SMN1; SMN2MEN1KMT2AHTTGALR3 | |
| SCHEMBL12763789 | 0.75 | TLR7 (0.66) | SMN1; SMN2MEN1KMT2AHTTGALR3 | |
| SCHEMBL3056940 | 0.75 | MEN1 (0.51) | MEN1KMT2AHTTGALR3CYP2C19 | |
| SCHEMBL898599 | 0.74 | CYP2D6 (0.42) | SMN1; SMN2MEN1KMT2ARAB9ACYP2C19 | |
| SCHEMBL4855474 | 0.74 | HTT (0.75) | SMN1; SMN2MEN1KMT2AHTTGALR3 | |
| SCHEMBL5236710 | 0.73 | OPRK1 (0.73) | SMN1; SMN2MEN1KMT2AHTTGALR3 | |
| SCHEMBL5053541 | 0.73 | HTT (0.73) | SMN1; SMN2MEN1KMT2AHTTGALR3 | |
| SCHEMBL4852085 | 0.73 | HTT (0.73) | SMN1; SMN2MEN1KMT2AHTTGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2621903-A1 | N-HETEROARYL COMPOUNDS | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | SMN1; SMN2 4016/4885MEN1 1940/4885KMT2A 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.